Scarica l'app Stockscreener
15.24
3.69%
-0.475
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché AVTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$15.72
Aprire:
$15.75
Volume 24 ore:
40,899
Relative Volume:
0.04
Capitalizzazione di mercato:
$818.13M
Reddito:
$59,000
Utile/perdita netta:
$-84.74M
Rapporto P/E:
-2.6184
EPS:
-5.8222
Flusso di cassa netto:
$-59.69M
1 W Prestazione:
-8.63%
1M Prestazione:
-23.30%
6M Prestazione:
+8.53%
1 anno Prestazione:
+31.08%
Intervallo 1D:
$15.00
$15.75
Intervallo di 1 settimana:
$14.58
$16.86
Portata 52W:
$10.70
$24.27
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Nome
Avalo Therapeutics Inc
Settore
Industria
Telefono
410-522-8707
Indirizzo
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
15.26 | 843.06M | 59,000 | -84.74M | -59.69M | -5.8222 |
VRTX
Vertex Pharmaceuticals Inc
|
521.26 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
789.50 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.78 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
960.03 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.36 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-09 | Iniziato | Wolfe Research | Outperform |
| 2026-04-06 | Iniziato | Citizens | Mkt Outperform |
| 2026-02-02 | Iniziato | Guggenheim | Buy |
| 2025-12-18 | Iniziato | Mizuho | Outperform |
| 2025-09-17 | Reiterato | H.C. Wainwright | Buy |
| 2025-09-05 | Iniziato | TD Cowen | Buy |
| 2025-08-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-06-02 | Ripresa | H.C. Wainwright | Buy |
| 2025-03-25 | Iniziato | Jefferies | Buy |
| 2025-03-25 | Iniziato | Stifel | Buy |
| 2025-02-28 | Iniziato | Piper Sandler | Overweight |
| 2025-02-21 | Iniziato | Wedbush | Outperform |
| 2024-12-19 | Iniziato | BTIG Research | Buy |
| 2024-10-24 | Iniziato | H.C. Wainwright | Neutral |
| 2024-04-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-09-24 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Avalo Therapeutics Inc Borsa (AVTX) Ultime notizie
AVTX: Phase II success with abdakibart in HS drives phase III plans and pipeline expansion, backed by strong cash reserves - TradingView
Avalo Therapeutics at Stifel forum: hs push gains traction By Investing.com - Investing.com Canada
Avalo Therapeutics, Inc. (AVTX) Stock Price, News, Quote & History - Yahoo Finance
Trial results for a chronic skin-condition drug are set for a late-breaking talk in Vienna - Stock Titan
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress - GlobeNewswire
Avalo Therapeutics CFO Christopher Sullivan Executes Option Exercise and Sells 12,394 Shares via 10b5-1 Plan - Kalkine Media
Avalo Therapeutics (AVTX) CFO sells 12K shares after option exercise - Stock Titan
Avalo Therapeutics Inc. (AVTX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Price-Driven Insight from (AVTX) for Rule-Based Strategy - Stock Traders Daily
Avalo Therapeutics at H.C. Wainwright conference: phase 2 data lift outlook - Investing.com
Cantor Fitzgerald reiterates Avalo Therapeutics stock rating - Investing.com
Cantor Fitzgerald reiterates Avalo Therapeutics stock rating By Investing.com - Investing.com India
AVTX 8-K FilingsAvalo Therapeutics, Inc. SEC 8-K - Stock Titan
Avalo Therapeutics (AVTX) CFO sells shares at $17.62 average, keeps 105K options - Stock Titan
Avalo Therapeutics at Cantor conference: building around il-1 beta By Investing.com - Investing.com Canada
(AVTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Avalo Therapeutics Inc. (AVTX) Peer Comparison – Compare with Others - Value Research
Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise (NASDAQ:AVTX) - Seeking Alpha
Avalo Therapeutics Inc. (AVTX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Avalo Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com India
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock - Investing.com
Avalo Therapeutics CFO Sullivan sells over $1.4m in stock By Investing.com - Investing.com Canada
Avalo Therapeutics CFO Sullivan sells over $1.4m in stock - Investing.com
Avalo Therapeutics (AVTX) CMO trades shares under 10b5-1 plan - Stock Titan
Avalo Therapeutics Inc. (AVTX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
How Avalo Therapeutics Inc. (AVTX) Affects Rotational Strategy Timing - Stock Traders Daily
Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares By Investing.com - Investing.com Nigeria
Avalo Therapeutics CFO sells over $1.45 million in stock By Investing.com - Investing.com Nigeria
Avalo Therapeutics CFO sells over $1.45 million in stock - Investing.com
AVTX | Avalo Therapeutics, Inc. Common FinancialsRevenue Breakdown - quiverquant.com
Avalo Therapeutics, Inc. Revenue Breakdown – NASDAQ:AVTX - TradingView
Deep Track Capital, LP Expands Avalo Therapeutics Inc (AVTX) Sta - GuruFocus
Avalo (AVTX) Q2 2026 Earnings: The EPS Result Is Below Expectation in the Latest Session; Post-Report: Shares Move 5.28% UpRevenue Growth Outlook - vinanet.vn
Avalo Therapeutics CMO Mittie Doyle Executes Stock Option and Sells 1,000 Shares Under 10b5-1 Plan - Kalkine Media
Avalo Therapeutics (AVTX) CMO sells 1,000 shares in plan - Stock Titan
Avalo Therapeutics Insider Sold Shares Worth $1,450,419, According to a Recent SEC Filing - marketscreener.com
Avalo Therapeutics (AVTX) CFO sells 72K shares in 10b5-1 trades - Stock Titan
Avalo (AVTX) Financial Update: Profit Per Share Falls Below Its Benchmark in Latest Trading; Post-Report - vinanet.vn
Avalo Therapeutics (NASDAQ: AVTX) insider lines up new stock sale after $74K August trade - Stock Titan
Avalo Therapeutics (AVTX) insider lines up $98.7K stock sale - Stock Titan
Avalo Therapeutics, Inc. SEC Filing (Aug 17, 2026) - Stock Titan
Avalo Therapeutics (NASDAQ: AVTX) insider to sell shares - Stock Titan
AVTX Q2 2026 Earnings: Wider-than-Expected Loss of -$0.83 Per Share Highlights Clinical-Stage BurnRevenue Growth Report - Vinanet
Wall Street Zen Upgrades Avalo Therapeutics (NASDAQ:AVTX) to Hold - marketbeat.com
Why Did AVTX Stock Surge 45% In Pre-Market Today? - Stocktwits
Avalo Therapeutics CMO Mittie Doyle sells $13,580 in stock By Investing.com - Investing.com Australia
Avalo Therapeutics CSO Jennifer Riley sells $52,012 in stock By Investing.com - Investing.com Canada
Avalo Therapeutics CSO Jennifer Riley sells $52,012 in stock - Investing.com
Avalo Therapeutics CMO Mittie Doyle sells $13,580 in stock - Investing.com
Avalo Therapeutics Inc Azioni (AVTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.82%
0.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):